Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320850 · ClinicalTrials.gov registry record · Phase 2
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 383
- Enrollment target
NCT03320850 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 383 participants.
The verdict
NCT03320850, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 383 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in participants with overactive bladder and urinary incontinence.
Interventions
- DRUG OnabotulinumtoxinA and Hydrogel admixture
- DRUG Placebo and Hydrogel admixture
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2020-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03320850
The ClinicalTrials.gov registry entry for NCT03320850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OnabotulinumtoxinA and Hydrogel admixture is the first listed.
NCT03320850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03320850 about?
NCT03320850 is a clinical study titled "BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence". This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in participants with overactive bladder and urinary incontinence.
What is the current status of trial NCT03320850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 383 participants. The study started on 2017-10-04. Estimated completion is 2020-07-21.
What interventions are being tested in trial NCT03320850?
The interventions under investigation include: OnabotulinumtoxinA and Hydrogel admixture (DRUG), Placebo and Hydrogel admixture (DRUG).
Who is sponsoring clinical trial NCT03320850?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.